BPG is committed to discovery and dissemination of knowledge
Articles in Press
5/12/2022 7:44:50 PM | Browse: 12 | Download: 28
Publication Name World Journal of Clinical Cases
Manuscript ID 72745
Country/Territory China
Category Hematology
Manuscript Type Case Report
Article Title Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy
Manuscript Source Unsolicited Manuscript
All Author List Yuan-Yuan Hao, Pan-Pan Chen, Xiang-Gui Yuan, Ai-Qi Zhao, Yun Liang, Hui Liu and Wen-Bin Qian
Funding Agency and Grant Number
Corresponding Author Wen-Bin Qian, MD, PhD, Doctor, Professor, Department of Hematology, The Second Affiliated Hospital of Zhejiang University School of Medicine, No. 88 Jiefang Road, Hangzhou 310009, Zhejiang Province, China. qianwb@zju.edu.cn
Key Words Chimeric antigen receptor T cell therapy; Diffuse large B-cell lymphoma; Immunotherapy; PD-1 inhibitor; Histone deacetylase inhibitor; Case report
Core Tip We used histone deacetylase inhibitor chidamide combined with PD-1 blockade sintilimab for 7 patients with diffuse large B-cell lymphoma progressing after CART therapy. There are 2 complete response rates (CRs) and 2 PRs during this novel therapy, with an overall response rates of 57.1%, and one patient had a durable CR that lasted at least 20 mo.
Citation Hao YY, Chen PP, Yuan XG, Zhao A, Liang Y, Liu H, Qian W. Histone deacetylase inhibitor chidamide and PD-1 blockade combination in diffuse large B-cell lymphoma progressing after CD19-targeting chimeric antigen receptor T cells therapy. World J Clin Cases 2022; In press
2021-10-31 03:52
Peer-Review Started
2021-10-31 03:53
To Make the First Decision
Return for Revision
2022-03-07 02:03
2022-04-10 06:51
Second Decision
2022-05-11 03:02
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2022-05-12 19:44
Articles in Press
2022-05-12 19:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
2022-05-03 00:12
Typeset the Manuscript
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Assistant Editor Assistant Editor
Science Editor Yun-Xiaojian Wu
Reviewer Code 00506472, 02510220, and 03739641
Editorial Director
Journal Chief Editor
Company Chief Editor Li Ma
Language Editor Donna Fox
Production Editor
Responsible Production Editor
Responsible Science Editor
Proofing Editorial Director Jin-Lei Wang
Proofing Editor-in-Chief Lian-Sheng Ma
Manuscript File 72745_Auto_Edited_LM.docx
Answering Reviewers 72745-Answering reviewers.pdf
Audio Core Tip 72745-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 72745-Conflict-of-interest statement.pdf
Copyright License Agreement 72745-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s) 72745-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate 72745-Language certificate.pdf
Peer-review Report 72745-Peer-review(s).pdf
Scientific Misconduct Check 72745-Bing-Wu YXJ-2.png
Scientific Editor Work List 72745-Scientific editor work list.pdf